Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (18)

G. Morrish(1), C.Kirkpatrick(1), N. Byrne(2), H. Kinoshita(3) & B. Green(1)

Using Body Composition Metrics to Predict Exposure Between Japanese and Caucasian Populations

C. Becker(1), K. Coboeken(1), L. Kuepfer(1), J. Lippert(1), R. Nubbemeyer(2), H. Blode(2)

Whole-Body Physiologically-based Pharmacokinetic (WB-PBPK) Population Modelling to Simulate the Influence of Weight and Age on the Pharmacokinetics (PK) of a combined Oral Contraceptive Containing Drospirenone (DRSP) and Ethinylestradiol (EE)

Yumi Emoto, Satofumi Iida, Hidenobu Aso, Haruki Kinoshita

Evaluation of Population PK/PD for Osteoporosis during a Vitamin D3 (1,25(OH)2D3) Derivative Therapy

Elke H.J. Krekels1,2, Gijs W.E. Santen1, John N. van den Anker2,3, Joost de Jongh1,4, Evelyne M. Jacqz-Aigrain5, Caroline D. van der Marel2,6, Richard A. van Lingen7, Anne M. Lynn8, Monique van Dijk2, Sinno Simons2, Meindert Danhof1, Dick Tibboel2, Catherijne A.J. Knibbe1,2,9

Development AND External validation of a model for Glucuronidation in children below 3 years of age using morphine as a model drug; towards a novel dosing paradigm.

Mariska Y.M. Peeters(1), Karel Allegaert(2), Heleen Blussé van Oud-Alblas(3,4), Massimo Cella(5), Dick Tibboel(4), Meindert Danhof(5), Catherijne A.J. Knibbe(1,4,5)

Predictive Value of Allometric Scaling for Estimation of Propofol Clearance in Neonates, Infants and Adolescents

Susan Willavize(1) , Ruolun Qiu (1), Marc Gastonguay (2)

Using M&S to Shorten the Repeating Cycle of the Early Drug Development Process: A Case Study

Susan Willavize

Dose Selection for Combination Drug Products

J. Smeets(1), B. Ploeger(1), A. Strougo(1), L. Liefaard(1), T. Kerbusch(2)

A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function

S. Fanta(1), S. Jönsson(2), M.O. Karlsson(3), C. Holmberg(4), K. Hoppu(1), J.T. Backman(1)

Population Pharmacokinetics of Cyclosporine in Paediatric Renal Transplant Recipients

Pascal Chanu (1), Bruno Reigner (1), Nathalie Schultze (1), Ronald Gieschke (1), Nicolas Frey (1)

Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class

F T Musuamba (1), J L Bosmans(2), J J Senessael (3), J Cumps (1), P Wallemacq (4) and R K Verbeeck (1)